Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
uniQure: Why A Shifting FDA Could Change Everything For AMT-130
11:14am, Monday, 01'st Jun 2026
uniQure remains highly sensitive to AMT-130's regulatory outcome, with current valuation reflecting significant uncertainty around FDA approval. Recent FDA leadership changes and a scheduled Type B me
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play
10:24am, Tuesday, 12'th May 2026
UniQure is upgraded from Hold to Buy, driven by near-term UK approval prospects for AMT-130 and a robust cash runway to 2029. Despite FDA requiring a new Phase 3 trial for AMT-130 in Huntington's, a U
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
03:41pm, Tuesday, 05'th May 2026
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
09:26am, Tuesday, 05'th May 2026
uniQure (QURE) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.82 per share a year ago.
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
07:05am, Tuesday, 05'th May 2026
~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
07:05am, Thursday, 30'th Apr 2026
~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~
uniQure to Announce First Quarter 2026 Financial Results
07:05am, Tuesday, 28'th Apr 2026
~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE
03:10pm, Monday, 13'th Apr 2026
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
01:51pm, Monday, 13'th Apr 2026
New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed again
NEW YORK--(BUSINESS WIRE)---- $QURE #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V. (“uniQure” or the “Company�
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
09:00am, Monday, 13'th Apr 2026
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
11:54pm, Sunday, 12'th Apr 2026
LOS ANGELES, April 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
11:53pm, Sunday, 12'th Apr 2026
LOS ANGELES, April 12, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Com
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
01:31pm, Sunday, 12'th Apr 2026
NEW YORK, April 12, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and Octobe
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired
